Why the study?
Neonatal Marfan syndrome is a rare form with poor prognosis, where most patients die during infancy due to severe, rapidly progressive cardiovascular disorders.
Does early mitral valve replacement improve outcomes in infants with neonatal Marfan syndrome and severe valvular regurgitation?
Does early mitral valve replacement improve outcomes in infants with neonatal Marfan syndrome and severe valvular regurgitation?
Early mitral valve replacement may be a viable and life-saving option for infants with neonatal Marfan syndrome presenting with severe valvular regurgitation.
May support early MVR consideration in critical cases; leaves open need for prospective studies on timing and outcomes.
Marfan syndrome is an autosomal dominant genetic disorder of the fibrous connective tissue caused by pathogenic mutations in the fibrillin-1 gene. Neonatal Marfan syndrome is a rare type of Marfan syndrome that is genotypically and phenotypically different from classical Marfan syndrome and has a poor prognosis. Most patients with neonatal Marfan syndrome die during infancy due to severe and rapidly progressive cardiovascular disorders. Here, we present a case of an 11-year-old girl with neonatal Marfan syndrome due to a novel missense mutation in exon 27 of the fibrillin-1 gene. Her condition was critical due to progressive mitral and tricuspid regurgitation. Mitral valve replacement, performed at the age of 6 months, improved her critical condition. Our case suggests that early mitral valve replacement may lead to better outcomes in patients with neonatal Marfan syndrome.
No takes yet. Share an insight, caveat, or question.
Motonaga et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: